Zevra Therapeutics | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 39.66 M

Revenue: As of FY2026 Q2, the actual value is USD 39.66 M, beating the estimate of USD 33.88 M.

EPS: As of FY2026 Q2, the actual value is USD 0.14, beating the estimate of USD 0.1089.

EBIT: As of FY2026 Q2, the actual value is USD 16.78 M.

Net Revenue

Zevra Therapeutics, Inc. reported $39.7 million in net revenue for Q2 2026, which is a 53% increase compared to $25.9 million in Q2 2025. This included $30.2 million from MIPLYFFA, $0.2 million from OLPRUVA, $9.0 million in net reimbursements from its global Expanded Access Program (EAP), and $0.3 million from past due royalties and other reimbursements under the AZSTARYS® license agreement.

Cost of Product Revenue

Cost of product revenue for Q2 2026 was - $1.5 million, excluding non-cash intangible asset amortization, compared to - $12.4 million in Q2 2025.

Operating Expenses

Total operating expenses for Q2 2026 were - $21.0 million, a decrease from - $24.2 million in Q2 2025. Research and Development (R&D) expense increased to - $4.5 million in Q2 2026 from - $3.4 million in Q2 2025, primarily due to increased spending on arimoclomol efforts. Selling, General and Administrative (SG&A) expense decreased to - $16.6 million in Q2 2026 from - $20.8 million in Q2 2025, mainly due to reductions in professional fees and third-party spending, partially offset by higher personnel costs.

Net Income

Net income for Q2 2026 was $8.8 million, compared to $74.7 million in Q2 2025. Excluding certain one-time charges and gains, adjusted quarterly net income was an estimated $15.2 million for Q2 2026, compared to an adjusted net loss of - $2.4 million for Q2 2025.

Cash Position

As of June 30, 2026, Zevra Therapeutics, Inc. held $260.2 million in cash, cash equivalents, and investments.

Operational Metrics

MIPLYFFA® (arimoclomol)

In Q2 2026, 14 MIPLYFFA prescription enrollment forms were received, bringing the total to 184 since product launch. Market access remains stable at 69% of covered lives.

Global Expanded Access Program (EAP)

As of June 30, 2026, 132 patients were enrolled in the global EAP.

Celiprolol (Vascular Ehlers-Danlos Syndrome)

Four patients were enrolled in the Phase 3 DiSCOVER trial for celiprolol during Q2 2026, bringing the total enrolled to 66 patients, with three confirmed events.

Outlook / Guidance

Zevra Therapeutics, Inc. plans to engage with the U.S. Food and Drug Administration (FDA) in the second half of 2026 to explore accelerated clinical development pathways for celiprolol. The Company is also seeking access to arimoclomol in Europe by requesting a re-examination of its Marketing Authorisation Application. Based on its current operating forecast, Zevra Therapeutics, Inc. believes its available financial resources are sufficient to execute strategic priorities independently of capital markets.